Dr. Milner is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
14690 Manuella Rd
Los Altos Hills, CA 94022Phone+1 650-941-7807
Education & Training
University of Virginia Medical CenterFellowship, Cardiovascular Disease, 1984 - 1986
Johns Hopkins UniversityResidency, Internal Medicine, 1981 - 1984
Univ Liverpool- Fac MedClass of 1980
Certifications & Licensure
MO State Medical License 1987 - 2026
MD State Medical License 1987 - 1987- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Cardiovascular Disease
Awards, Honors, & Recognition
- Fellow (FACC) American College of Cardiology
Clinical Trials
- A Study to Assess Efficacy and Safety of RT001 in Subjects With Infantile Neuroaxonal Dystrophy Start of enrollment: 2018 Nov 05
- Natural History of Infantile Neuroaxonal Dystrophy Start of enrollment: 2018 Jul 30
- A Natural History Study of Infantile Neuroaxonal Dystrophy Start of enrollment: 2019 Jun 17
Publications & Presentations
PubMed
- 10 citationsPharmacokinetics of Tecarfarin and Warfarin in Patients with Severe Chronic Kidney Disease.Detlef Albrecht, Mintu P. Turakhia, Daniel Ries, Thomas Marbury, William K. Smith
Thrombosis and Haemostasis. 2017-11-30 - 11 citationsPharmacokinetics and pharmacodynamics of tecarfarin, a novel vitamin K antagonist oral anticoagulantDetlef Albrecht, David J. Ellis, Daniel M. Canafax, Daniel Combs, Pascal Druzgala
Thrombosis and Haemostasis. 2017-02-09 - 8 citationsA randomised, double blind comparison of tecarfarin, a novel vitamin K antagonist, with warfarin. The EmbraceAC Trial.Richard P. Whitlock, Christopher B. Fordyce, Mark G. Midei, Dave J. Ellis, David A. Garcia
Thrombosis and Haemostasis. 2016-05-12
Press Mentions
Renexxion Ireland Ltd. And Dr. Falk Pharma GmbH Announce Initiation of Phase II Study of Naronapride in Patients with GastroparesisFebruary 15th, 2023- Renexxion Ireland Ltd. And Dr. Falk Pharma GmbH Announce Initiation of Phase II Study of Naronapride in Patients with GastroparesisFebruary 15th, 2023
- Renexxion Seeks FDA OK to Test Naronapride for GI Problems in CFJanuary 11th, 2023
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
